stockrowInflaRx N.V.
IFRXInflaRx N.V.’s revenue for fiscal 2025 (year ended December 2025) was $33,200.00, down 81.5% from fiscal 2024.
- Revenue
- −128.9%
- EPS
- +90.9%
- Free cash flow
- +59.8%
Quarter to September 2026, against a year earlier
Follow IFRX
Alert me
InflaRx N.V. (IFRX) Return on invested capital
InflaRx N.V.'s return on invested capital over the twelve months to 30 September 2026 was −87.3%, down 87.3 percentage points from fiscal 2025 (0.00%). Over the past ten years it has ranged from −1,042.2% (fiscal 2024) to 0.00% (fiscal 2025) — the current reading is the highest in ten years. That is below the Biotechnology industry median of 0.00% and below the Healthcare sector median of 0.00%.
Return on invested capital, annual
Embed this chart
Annual newest first
| Period | Return on invested capital | Change (points) |
|---|---|---|
| FY2025 | 0.00% | 1,042.21 |
| FY2024 | −1,042.2% | (747.07) |
| FY2023 | −295.1% | 205.52 |
| FY2022 | −500.7% | (364.37) |
| FY2021 | −136.3% | (136.29) |
| FY2020 | 0.00% | 0.00 |
| FY2019 | 0.00% | 0.00 |
| FY2018 | 0.00% | 0.00 |
| FY2017 | 0.00% | 0.00 |
| FY2016 | 0.00% | — |
Against its own ten years
Return on invested capital against peers
| Company | Return on invested capital |
|---|---|
| PLX Protalix BioTherapeutics, Inc. compare | 48.5% |
| PALI Palisade Bio, Inc. compare | 0.00% |
| RNAC Cartesian Therapeutics, Inc. compare | 0.00% |
| ARTV Artiva Biotherapeutics, Inc. compare | 0.00% |
| DRUG Bright Minds Biosciences Inc. compare | 0.00% |
| IKT Inhibikase Therapeutics, Inc. compare | 0.00% |
| ELDN Eledon Pharmaceuticals, Inc. compare | 0.00% |
| IFRX InflaRx N.V. | −87.3% |
| SLGL Sol-Gel Technologies Ltd. compare | −6,630.2% |
| Biotechnology industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Return on invested capital is
Return on Invested Capital shows how much after-tax operating profit a company earns on the money its lenders and shareholders have put in.
TTM: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) (latest quarter) + Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter) − Cash & Short Term Investments (latest quarter)); Annual: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) + Long Term Debt (Total) + Current Part of Debt − Cash & Short Term Investments)